Archimed closed its MED IV healthcare investment fund at €1.5 billion, exceeding its original €1.2 billion target and attracting three-times oversubscription. The firm said it will deploy capital across biopharma, consumer health, diagnostics, healthcare IT, medtech, and life-science tools and services. The close reflects continued institutional confidence in healthcare as a multi-vertical investment theme, even as company-level execution risk remains high for early-stage programs. For founders and portfolio companies, a larger dedicated vehicle can translate into more follow-on capacity, faster syndication, and greater room to navigate clinical or regulatory timelines.